Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure 11During publication process the following related paper has been published by Vejlstrup NG, Bouloumie A, Boesgaard S, Andersen CB, Nielsen-Kudsk JE, Mortensen SA, Kent JD, Harrison DG, Busse R, Alsershvile J. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure. J Mol Cell Cardiol 1998;30:1215–23.  by Stein, Birgitt et al.
Increased Expression of Constitutive Nitric Oxide Synthase III, but
not Inducible Nitric Oxide Synthase II, in Human Heart Failure
BIRGITT STEIN, PHD,* THOMAS ESCHENHAGEN, MD,* JOCHEN RU¨DIGER, MS,*
HASSO SCHOLZ, MD,* ULRICH FO¨RSTERMANN, MD, PHD,† INGOLF GATH, PHD†
Hamburg and Mainz, Germany
Objectives. The purpose of the present study was to examine the
expression of the endothelial-type nitric oxide synthase (NOS III)
and the inducible-type NOS (NOS II) in human myocardium and
their regulation in heart failure from patients with different
etiologies.
Background. In heart failure, plasma levels of nitrates were
found to be elevated. However, data on myocardial NOS expres-
sion in heart failure are conflicting.
Methods. Using RNase protection analysis and Western blot-
ting, the expression of NOS III and NOS II was investigated in
ventricular myocardium from nonfailing (NF) hearts (n 5 5) and
from failing hearts of patients with idiopathic dilated cardiomy-
opathy (dCMP, n 5 14), ischemic cardiomyopathy (iCMP, n 5 9)
or postmyocarditis cardiomyopathy (mCMP, n 5 7). Further-
more, immunohistochemical studies were performed to localize
NOS III and NOS II within the ventricular myocardium.
Results. In failing human hearts, NOS III mRNA levels were
increased to 180% in dCMP, 200% in iCMP and to 210% in mCMP
as compared to NF hearts. Similarly, in Western blots (using
constitutively expressed beta-tubulin as a reference) NOS III
protein expression was increased about twofold in failing com-
pared to NF hearts. Immunohistochemical studies with a selective
antibody to NOS III showed no obvious differences in the staining
of the endothelium of cardiac blood vessels from NF and failing
human hearts. However, NOS III-immunoreactivity in cardiomy-
ocytes was significantly more intense in failing compared to NF
hearts. Low expression of NOS II mRNA was detected in only 2 of
30 failing human hearts and was not found in NF hearts.
Inducible-type NOS protein was undetectable in either group.
Conclusions. We conclude that the increased NOS III expres-
sion in the ventricular myocardium of failing human hearts may
contribute to the contractile dysfunction observed in heart failure
and/or may play a role in morphologic alterations such as
hypertrophy and apoptosis of cardiomyocytes.
(J Am Coll Cardiol 1998;32:1179–86)
©1998 by the American College of Cardiology
Nitric oxide (NO) is enzymatically formed from L-arginine by
three isoforms of NO synthase (NOS) (1). Whereas the
neuronal-type NOS I and the endothelial-type NOS III are
constitutive low-output, Ca21-activated enzymes, the cytokine-
inducible NOS II is a Ca21-independent high-capacity enzyme.
There is evidence that NO reduces myocardial contractility
by different mechanisms (2–14, reviewed in 15). This has been
shown for high concentrations of NO, as produced by the
inducible isoform of NOS (NOS II). Interestingly, also physi-
ologic concentrations of NO, as produced by Ca21-dependent
isoforms of NOS, seem to be sufficient for this effect (15).
Nevertheless, the physiologic as well as the pathophysiologic
role of L-arginine-derived NO in regulating myocardial con-
tractility remain controversial (16–20, reviewed in 21).
One uncertainty refers to heart failure. Congestive heart
failure is characterized by contractile dysfunctions, for exam-
ple, diminished contractile response to beta-adrenergic ago-
nists (22), attenuated force-frequency-relationship (23) and
various morphologic as well as cellular abnormalities, for
example, hypertrophy (24), apoptosis (25) and changes in
calcium handling (26). Some of these defects have been
proposed to be associated with a stimulation of the
L-arginine-NO system (11,27). However, there is controversy
as to whether NOS II is expressed in the myocardium of failing
human hearts. De Belder et al. (28,29) reported increased
enzyme activity of a Ca21-independent NOS in the myocar-
dium of patients with dilated cardiomyopathy, myocarditis and
postpartum cardiomyopathy, but not in ischemic or valvular
heart disease. Others demonstrated NOS II mRNA and im-
munoreactivity in hearts from patients with dilated cardiomy-
opathy (30–32), but also in ischemic and valvular heart disease
(30). In previous studies we have found NOS II immunoreac-
During publication process the following related paper has been published
by Vejlstrup NG, Bouloumie A, Boesgaard S, Andersen CB, Nielsen-Kudsk JE,
Mortensen SA, Kent JD, Harrison DG, Busse R, Alsershvile J. Inducible nitric
oxide synthase (iNOS) in the human heart: Expression and localization in
congestive heart failure. J Mol Cell Cardiol 1998;30:1215–23.
From the *Institu¨t fu¨r Experimentelle und Klinische Pharmakologie u¨nd
Toxikologie, Abteilung Pharmakologie, Universita¨ts-Krankenhaus Eppendorf,
Universita¨t Hamburg, Hamburg; and †Pharmakologisches Institut, Universita¨t
Johannes-Gutenberg, Mainz, Germany. The study was supported by the Deut-
sche Forschungsgemeinschaft, SFB 553/Project A1. This work is part of the
doctoral thesis of J. Ru¨diger at the University of Hamburg and has been
presented in abstract form (Naunyn Schmiedebergs Arch Pharmacol 1996;353:
R60).
Manuscript received September 23, 1997; revised manuscript received June
15, 1998, accepted June 22, 1998.
Address for correspondence: Dr. Birgitt Stein, Institu¨t fu¨r Experimentelle
und Klinische Pharmakologie u¨nd Toxikologie, Abteilung Allgemeine Pharma-
kologie, Universita¨ts-Krankenhaus Eppendorf, Universita¨t Hamburg, Martinis-
traße 52, 20246 Hamburg, Germany.
JACC Vol. 32, No. 5
November 1, 1998:1179–86
1179
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00399-4
tive protein only in septic hearts, but not in other forms of
cardiomyopathy (33). In the current study we confirm the lack
of significant expression of NOS II mRNA and protein in
human hearts with different forms of cardiomyopathy. Since
there are no reports concerning the expression of NOS III in
ventricular myocardium from patients with heart failure, we
investigated additionally NOS III gene expression. Nitric oxide
synthase protein has been demonstrated in atrial tissue from
nonfailing (NF) human hearts (34) and rat ventricular cardio-
myocytes (9,10). Recent studies demonstrated that in vivo gene
transfection of NOS III in cardiomyocytes caused apoptosislike
cell death, thereby mimicking the morphologic features of
acute myocarditis or ischemic injury (27). Moreover, given the
modulating activity of NOS III-derived NO on the inotropic
effects of beta-blockers and cholinergic agonists (8–12) as well
as the force-frequency-relation (13,14), we hypothesized that
an increased expression of the endothelial-type NOS III may
occur in human heart failure and contribute to the contractile
and/or morphologic abnormalities.
Here we report an increased expression of NOS III mRNA
and protein in various forms of human cardiomyopathy, using
RNase protection analysis, Western blotting and immunohis-
tochemistry.
Methods
Myocardial tissue. Failing human hearts were obtained
from patients undergoing heart transplantation because of
end-stage heart failure due to idiopathic dilated cardiomyop-
athy (dCMP, n 5 14) ischemic cardiomyopathy (iCMP, n 5 9)
or postmyocarditis cardiomyopathy (mCMP, n 5 7). Criteria
used for the differentiation between iCMP and mCMP were 1)
anamnestic or histologic evidence for myocarditis or the pres-
ence of specific antibody titers in the serum and 2) the lack of
coronary stenosis as confirmed by left heart catheterization.
All patients were classified as New York Heart Association
class IV with markedly abnormal pretransplant hemodynamics.
Mean cardiac index was 1.85 6 0.13 (dCMP), 1.72 6 0.09
(iCMP) and 1.97 6 0.19 (mCMP) L/min 3 m2; mean pulmo-
nary capillary wedge pressure was 21.36 6 1.85 (dCMP),
28.00 6 6.40 (iCMP) and 28.00 6 1.41 (mCMP) mm Hg; left
ventricular ejection fraction was 19.0 6 1.0% (dCMP), 19.0 6
3.0% (iCMP) and 18.0 6 2.0 mCMP. Mean age was 48.9 6 1.4
(dCMP), 51.0 6 1.8 (iCMP), 35.0 6 6.0 (mCMP) and 38.4 6
6.9 years NF control hearts (n 5 5), respectively. Prior to
cardiectomy all patients received conventional medical
treatment including cardiac glycosides, nitrates, diuretics,
angiotensin-converting enzyme inhibitors and other vasodila-
tors in varying combinations. No patient received cat-
echolamines, alpha- or beta-adrenoceptor agonists or antago-
nists or phosphodiesterase inhibitors. Nonfailing control hearts
were obtained from prospective multiorgan donors without
cardiovascular pathology, which could not be transplanted due
to technical reasons. Procedures for obtaining human tissue
complied with the Helsinki Declaration. Permission for these
experiments was obtained from the local Ethics Committee.
Written informed consent was taken from all patients or the
family of prospective heart donors before cardiectomy. Tissue
samples from the free wall of left ventricles (dCMP n 5 14;
iCMP n 5 9; mCMP n 5 3; NF n 5 5) or right ventricles
(mCMP n 5 4) were obtained at the time of explantation and
rapidly frozen in liquid nitrogen. Care was taken not to take
scarred, fibrotic or adiposed tissue; endocard and epicard or
great vessels were removed. Tissue samples were stored at
280°C until further use.
RNA preparation and RNase protection assay. Total RNA
was extracted from left ventricular tissue samples (0.5 to 1.0 g)
by acid guanidium thiocyanate-phenol-chloroform extraction,
as described previously (35). RNA yields were 0.76 6 0.08
(NF), 0.68 6 0.04 (dCMP), 0.68 6 0.05 (iCMP) and 0.67 6
0.05 (mCMP) mg/mg tissue. The average OD260/280 was 1.95
(n 5 35). All RNA preparations were checked in 1% formal-
dehyde containing agarose gels. RNase protection assays were
performed with RPA II kit (Ambion Inc., Austin, Texas)
according to the manufacturer’s protocol with minor modifi-
cations. Plasmids (pBluescript) containing human NOS II or
NOS III cDNA-fragments were gifts from D.A. Geller (36;
Department of Medicine, University of Pittsburgh, Pittsburgh,
Pennsylvania) and P.A. Marsden (37; Department of Surgery,
University of Toronto, Toronto, Ontario, Canada). Antisense-
RNA probes for NOS II, NOS III and Gsa were generated by
in vitro transcription of 0.5 mg linearized plasmid DNA
(restriction of NOS II with Nae I and NOS III with Sma I)
using T3 or T7 RNA polymerase. The reaction was performed
in 13 transcription buffer (Ambion Inc.) containing ATP,
GTP, CTP (20 nmol/L, each), 50 mCi 32P-UTP (800 Ci/mM;
NEN, Dreieich, Germany), RNase inhibitor (40 U; Promega,
Madison, Wisconsin) and dithiothreitol (10 mmol/L) in a total
volume of 20 ml for for 2 h at 25°C. After transcription, the
reaction mix was treated with RNAse-free DNase I (20 U,
Boehringer, Mannheim, Germany) for 15 min at 37°C. Subse-
quently, the antisense-RNA probes were purified by 8M urea
gel electrophoresis (Long Ranger Gel, AT Biochem, Malvern,
Pennsylvania). The respective bands were cut out with sterile
razor blades under autoradiographic control, and RNA-probes
were eluted by overnight incubation in elution buffer (Ambion
Inc.) at 37°C. 32P-labeled NOS II and NOS III antisense-RNA
probes (50,000 disintegrations per minute [dpm], each) and
Gsa antisense-RNA probe (7,500 dpm) were hybridized (hy-
Abbreviations and Acronyms
dCMP 5 idiopathic dilated cardiomyopathy
iCMP 5 ischemic cardiomyopathy
mCMP 5 postmyocarditis cardiomyopathy
NF 5 nonfailing
NO 5 nitric oxide
NOS 5 nitric oxide synthase
NOS II 5 inducible-type nitric oxide synthase
NOS III 5 constitutive endothelial-type nitric oxide synthase
RT-PCR 5 reverse transcriptase-polymerase chain reaction
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bridization buffer from Ambion Inc.) with 10 to 30 mg of total
RNA at 45°C overnight. The reaction mix was digested with
RNase A/T1 (5 mg/ml and 100 U/ml, respectively) for 30 min at
37°C. Incubations of 32P-labeled antisense-probes (50,000 dpm
each) with tRNA were treated with RNases and served as
negative controls, others (2,000 dpm each) were treated with
solution Dx (Ambion Inc.) and served as positive controls.
After addition of solution Dx, the samples were incubated for
30 min at 280°C and then centrifuged at 15,000 3 g (15 min,
4°C). The pellets were resuspended in formamide containing
loading buffer (Ambion Inc.), denatured for 5 min at 95°C and
loaded onto a 5% polyacrylamide gel containing 8M urea.
Autoradiography of dried gels was performed at 220°C for 5
to 10 days.
Densitometric analyses of RNase protection assays were
performed using a Phosphoimager (ZERO-Dscan, Scanalytics,
Billerica, Massachusetts). Resulting densities and pixel values
were analyzed by ZERO-Dscan software. Five-point calibra-
tion curves were constructed with specific sense-orientated
RNAs (0.5 to 20 pg) for NOS II and NOS III that were
supplemented with 20 mg tRNA (Fig. 1). Sense-RNAs were
produced by in vitro transcription in the presence of trace
amounts (1:10,000) of 32P-UTP to monitor the incorporation
efficiency. Sizes of NOS II and NOS III sense-RNA were
2,121 nt for NOS II (2,060 nt cDNA plus 61 nt multiple cloning
site [MCS]) and 2,282 nt for NOS III (2,180 nt cDNA plus 102
nt MCS), respectively. The reaction usually yielded between 5
and 10 mg RNA that were purified by gel filtration on
Sephadex G-50, diluted to 100 pg/ml in TE/0.5% SDS and
stored at 280°C.
Pixel values of the NOS II and NOS III calibration curves
were fitted by linear regression. Density units of the signals for
protected fragments were referred to the respective calibration
curve and mRNA concentrations expressed as pg/mg total
RNA. Since the size of NOS III sense-RNA (2.2 kb) was about
half of the native NOS III mRNA (about 4.4 kb), the calcu-
lated yields were multiplied by the factor 2. To exclude minor
differences in RNA-loading, NOS signal intensities were cor-
rected by the signal for Gsa mRNA which has been demon-
strated to be unchanged in human heart failure (38). To obtain
comparable counts we used labeled antisense probes of
7,500 dpm for Gsa (specific activity ;1 3 108 dpm/mg)
compared to 50,000 dpm for NOS II or NOS III (specific
activity ;2 3 109 dpm/mg). The mean of all Gsa pixel values
on one gel was divided by the individual Gsa pixel value,
yielding a factor that expressed deviations from the average
and thereby loading differences. This factor was multiplied
with the respective NOS-mRNA value. Factors were 1.10 6
0.12 (NF, n 5 5), 1.19 6 0.08 (dCMP, n 5 14), 1.14 6 0.11
(iCMP, n 5 9) and 1.16 6 0.16 (mCMP, n 5 7). Correction by
this procedure did not alter the magnitude or the direction of
the results, but lowered the standard deviation.
Protein extraction and Western blotting. Tissue samples
from human heart transplants were homogenized in three
volumes of an ice-cold Tris-buffer (50 mmol/L Tris-HCl pH
7.5, 0.5 mmol/L EGTA, 0.5 mmol/L EDTA, 2 mmol/L dithio-
threitol, 7 mmol/L glutathione, 10% [v/v] glycerol, 10 mg/ml
pepstatin A, 20 U/l aprotinin, 10 mg/ml leupeptin and 0.2
mmol/L PMSF) using an Ultra-Turrax (Kinematica A6, Littau-
Luzern, Suisse). For solubilization of membrane-bound pro-
teins, homogenates were treated with the detergent 3-[(3-
cholamidopropyl)dimethylammonio]-1-propane-sulfonate
(CHAPS) at a final concentration of 20 mmol/L (rotating
shaker, 20 min at 4°). The CHAPS extracts were centrifuged at
160,000 3 g. Protein contents were measured in the resulting
supernatants with the micro-adapted Bradford (39) assay.
Proteins were separated by denaturing discontinuous poly-
acrylamide gel electrophoresis using 7.5% resolving gels and
blotted onto nitrocellulose membranes (Schleicher & Schuell,
Dassel, Germany) in a semi-dry electrophoretic transfer cell
(Trans-Blot, Bio-Rad, Munich, Germany). Blots were blocked
for 60 min with 3% (w/v) bovine serum albumin and 0.05%
(w/v) Tween 20 in TBS (10 mmol/L Tris/HCl, pH 7.4, in 0.9%,
w/v, NaCl). They were then incubated for 90 min at room
temperature with the primary antibody in TBS containing
0.5% (w/v) gelatin and 0.05% (w/v) Tween 20. The following
primary antibodies were used: a monoclonal anti-NOS II
antibody (1:1,500) and a polyclonal anti-NOS III antibody
(1:500), purchased from Transduction Laboratories (Lexing-
ton, Kentucky), and a monoclonal anti-beta-tubulin antibody
(1:500, Sigma Bio Sciences, Deisenhofen, Germany). Blots
were washed in TBS/gelatin/Tween and immunoreactive pro-
Figure 1. RNase protection analysis with antisense-RNA
probes specific for human NOS II and NOS III. In lane
1 the unhybridized NOS II and NOS III antisense-probes
are shown. Lanes 2 to 14 show hybridizations of the
respective RNA samples with both antisense-probes: 2,
total RNA from yeast (negative control); 3 to 10, increas-
ing amounts of NOS II and NOS III sense-RNA (3 to 4:
0.5 pg, 5 to 6: 2.5 pg, 7 to 8: 5 pg, 9: 10 pg, 10: 20 pg); 11
to 12, total RNA from NF human hearts; 13 to 14, total
RNA from failing human hearts.
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teins were visualized with NBT/X-phosphate (4-nitroblue tet-
razolium chloride/5-bromo-4-chloro-3-indolyl-phosphate) af-
ter a 60-min incubation with the secondary antibody
conjugated to alkaline phosphatase.
NOS III immunohistochemistry. Ten-micrometer sections
were prepared using a cryostat. Sections were thaw-mounted
onto poly-L-lysine-coated glass slides (Sigma), air-dried and
slightly fixed in ice-cold acetone for 5 to 10 s. First, sections
were washed in PBS for 10 min, and endogenous peroxidase
was blocked by incubation for 30 min in a freshly prepared
solution of 40% (v/v) methanol and 0.6% (v/v) H2O2 in PBS.
Blocking of endogenous biotin or biotin-binding proteins was
performed with a commercially available avidin/biotin-kit
(Camon, Wiesbaden, Germany). Thereafter, sections were
washed for 10 min in incubation medium (4% dry-milk powder
in PBS) and incubated with a 10% solution of normal serum
(Camon) from the species in which the secondary antibody was
generated. Incubation with the primary polyclonal anti-NOS
III antibody (Transduction Laboratories, 1:50) was performed
overnight at 4°C; sections were washed in incubation medium
and exposed to the secondary biotinylated antibody (Camon,
1:100) for 60 min at room temperature. This was followed by at
least two washes in PBS and incubation with a 1:100 dilution of
the streptavidin-biotinylated horseradish peroxidase complex
(Amersham, Buchler, Germany) in PBS for 20 min. After
repeated washing with PBS, the chromogen-reaction was per-
formed by the use of 3.39-diaminobenzidine (Sigma) according
to the instructions of the manufacturer. The sections were
washed in distilled water, counterstained with Mayer’s acid
hemalaum, mounted in glycerol gelatin and coverslipped.
Statistical analysis. All values presented are means 6
SEM. For statistical significance analysis of variance and
Student t test were used except for NOS III mRNA expression.
Secondary to its nonparametric distribution we used Kruskal–
Wallis’ rank test and Mann–Whitney U-test to compare NOS
III expression between NF and failing hearts. Bonferoni’s test
values , 0.05 were regarded as significant.
Results
RNase protection analysis. The in vitro transcription of
linearized plasmid DNA and subsequent purification of the
products resulted in homogenous bands of 32P-labeled
antisense-RNA probes for NOS II (619 nt), NOS III (505 nt)
and Gsa (403 nt) RNAs (Fig. 2). Hybridization of these probes
with the respective sense-RNAs gave protected fragments of
587 nt for NOS II (570 1 17 nt MCS) and 462 nt for NOS III
(433 1 29 nt MCS; Fig. 2, lane 6). Hybridization with total
RNA from ventricular tissue of NF or failing human hearts
resulted in protected fragments of 570 nt for NOS II, 433 nt for
NOS III and two fragments of 353 nt and 338 nt for Gsa (Fig.
2, lanes 8 to 22). As both antisense-probes and sense-RNAs
contained portions of the multiple cloning site, they differed in
their size from the respective protected fragments of total
RNA.
Quantification of NOS III-specific mRNA in NF human
hearts revealed 0.42 6 0.04 pg/mg total RNA (n 5 5, Fig. 3A).
Compared to NF hearts, NOS III-mRNA levels were increased
in failing human hearts to ;180% (0.77 6 0.09, n 5 14;
dCMP), ;200% (0.83 6 0.19, n 5 9; iCMP) and ;210%
(0.88 6 0.04, n 5 7; mCMP; Fig. 3A). Nitric oxide synthase-
mRNA levels tended to be increased also in iCMP, but this
effect did not reach significance. This is due to the unequal
distribution (nonparametric distribution) of the individual
values as demonstrated in Fig. 3B. Inducible-type NO-mRNA
expression was detected only in 7% (two out of 30, one dCMP
and one mCMP) of failing human hearts and was not detected
in NF hearts. On the other hand, in stimulated human
Figure 2. RNase protection analysis for the quantifica-
tion of NOS II- and NOS III-mRNA levels in total
RNA from left and right ventricular tissue of NF and
failing human hearts from patients with dilated cardio-
myopathy (dCMP), ischemic cardiomyopathy (iCMP)
or postmyocarditis cardiomyopathy (mCMP). Shown is
a representative autoradiogram. Lanes indicate: 1,
length marker; 2 to 5, unhybridized antisense-RNA
probes; 2, NOS II (619 nt); 3, NOS III (505 nt); 4, Gsa
(403 nt); 5, all three probes combined; 6 to 23, hybrid-
ization of the respective RNA samples with all three
antisense-RNA probes; 6, NOS II (587 nt) and NOS III
sense-RNA (462 nt); 7, 10 mg total RNA from yeast
(negative control), 8 to 22, 20 mg total RNA from NF
(8,15,16) and failing human hearts of patients with
dCMP (10,12,18,20), iCMP (9,11,14,17) or mCMP
(13,19,21,22); 23, 3 mg total RNA from stimulated
human hepatocytes (NOS II positive control, 570 nt).
Hybridization of total RNA from ventricular tissue with
NOS II antisense-RNA, but not with NOS II antisense-
RNA, yielded a protected fragment of the expected size
(433 nt for NOS III). Sizes of antisense-RNA probes
and protected fragments are given in parentheses in the
legend.
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hepatocytes (300 ng/ml LPS and 3 U/ml IFN-g, 18 h) the NOS
II antisense-probe hybridized to a single band of the expected
size for the NOS II, indicating that NOS II-mRNA expression
was detectable with the methods (Fig. 2, lane 23).
Western blotting and immunohistochemistry. On Western
blots, the monoclonal anti-NOS II antibody selectively stained
a protein of 130 kDa in homogenates of lipopolysaccharide-
induced RAW 264.7 macrophages (positive control for NOS II;
Fig. 4, upper panel). However, no band was detected by this
antibody in homogenates from NF or failing human hearts
(even though more protein was loaded). In contrast, significant
NOS III immunoreactivity was found in NF and failing myo-
cardium. This protein comigrated with a 135 kDa protein from
the particulate fraction of human EA.hy 926 endothelial cells
(40; positive control for NOS III; Fig. 4, lower panel). When
the NOS III immunoreactive signal from the heart samples was
normalized using the costained band of constitutively ex-
pressed beta-tubulin, failing hearts showed an increased NOS III
protein expression relative to NF hearts. The increase in iCMP
was 131% of control. The strongest augmentation in NOS III
protein was detected in samples from patients with mCMP
yielding to 221% of control (data are means of four observa-
tions). As expected, in immunohistochemical experiments, the
polyclonal anti-NOS III antibody clearly labeled the endothe-
lium of blood vessels in the different heart specimens. Staining
intensities of the endothelium of cardiac blood vessels were
comparable in samples from NF and failing hearts (Fig. 5,
panel A). Also in human cardiomyocytes from NF hearts, a
moderate NOS III-immunoreactivity was detected (Fig. 5,
panel B). Moreover, this immunoreactivity was markedly en-
hanced in cardiomyocytes from failing hearts. No apparent
differences in staining intensities in the cardiomyocytes were
detected between the different forms of cardiomyopathy.
Figure 3. NOS III-mRNA levels in nonfailing (NF) and failing (F)
human hearts from patients with dilated cardiomyopathy (dCMP),
ischemic cardiomyopathy (iCMP) and postmyocarditis cardiomyopa-
thy (mCMP) depicted as histogram (A) presenting means 6 SEM in
pg/mg total RNA, or as scatterdiagram (B) showing the individual pixel
values. F depicts summarized data from all failing hearts. *p , 0.05
versus NF.
Figure 4. Western blots of CHAPS-
solubilized protein from nonfailing
(NF) and failing human heart tis-
sues from patients with dilated car-
diomyopathy (dCMP), ischemic car-
d i o m y o p a t h y ( i C M P ) a n d
postmyocarditis cardiomyopathy
(mCMP). Electrophoreses were
performed in 7.5% resolving gels
and blots were immunostained with
anti-NOS II antibody (upper panel)
or anti-NOS III antibody (lower
panel). For normalization of the
NOS staining signal, blots were si-
multaneously immunostained with
an antibody to beta-tubulin. Positive
control proteins were included
(CHAPS-solubilized homogenates,
from lipopolysaccharide-induced
RAW 264.7 macrophages for NOS II
and from EA.hy 926 endothelial
cells for NOS III). Protein samples
were applied as follows: heart mus-
cle samples (75 mg protein/lane),
RAW 264.7 macrophages and
EA.hy 926 endothelial cells (20 and
40 mg protein/lane, respectively).
Results are representative of four
independent experiments with iden-
tical results.
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Discussion
In the current study we demonstrate an increase in the
expression of NOS III mRNA in left ventricular tissue from
failing compared with NF human hearts as determined by
quantitative RNase protection assay. Immunohistochemistry
with a selective antibody to NOS III showed no obvious
differences in the staining of the endothelium of cardiac blood
vessels from NF and failing hearts. However, NOS III-
immunoreactivity was significantly more intense in cardiomy-
ocytes from failing compared to NF hearts. Recently, the
expression of NOS III mRNA has been demonstrated in NF
human atrial tissue obtained from donor hearts being used for
cardiac transplantation (34). However, there are no reports on
NOS III expression in human heart failure, although there is
recent evidence for its involvement in animal models of heart
failure (41–43).
NOS II expression. Alterations in NOS II expression have
been reported in human heart failure (30–32). In the present
study, only 2 of 30 failing human hearts showed low expression
of NOS II mRNA as detected by quantitative RNase protec-
tion analysis. In NF hearts NOS II mRNA was totally absent.
Similarly, in Western blots, NOS II immunoreactivity was
detected neither in failing nor in NF hearts. This confirms and
extends our recent findings on different types of heart failure
demonstrating significant NOS II protein expression exclu-
sively in failing hearts from patients with sepsis (33). In
contrast, others found expression of NOS II in other types of
human heart failure (30–32). De Belder et al. (28,29) reported
significant Ca21-independent NOS activity in endomyocardial
biopsies from patients with dCMP, mCMP and postpartum
cardiomyopathy (suggesting the presence of NOS II), but not
in patients with ischemic or valvular heart disease. However,
Figure 5. Immunohistochemical localization of endothelial-
type NOS III in human heart. (A) Staining of blood vessels
within the myocardium. The anti-NOS III antibody selectively
stained vascular endothelium (dCMP 5 idiopathic dilated
cardiomyopathy; iCMP 5 ischemic cardiomyopathy;
mCMP 5 postmyocarditis cardiomyopathy and NF 5 nonfail-
ing heart). (B) Staining of cardiomyocytes (NF, dCMP, iCMP
and mCMP) on the same slices as the blood vessels in A.
Incubations with a rabbit nonimmune serum gave no staining
in the myocardium (Neg, negative control, slice object:
mCMP). The average diameter of cardiomyocytes from failing
hearts was increased compared to NF hearts. Magnification in
A and B 4003. Photomicrographs are representative of at least
four experiments with identical results.
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measurement of the Ca21-dependence of NOS enzymatic
activity does not allow an unequivocal isoform identification.
Previous immunohistochemical studies have detected strong
immunoreactivity for NOS II in myocytes from dCMP hearts,
but only moderately intense staining in myocytes from patients
with iCMP and no signal in hypertrophic or NF myocardium
(31,32). Haywood et al. (30), performing reverse transcription-
polymerase chain reaction (RT-PCR), described that NOS II
occurred in 67% of patients with dCMP, 59% of patients with
iCMP and in 100% of patients with valvular heart disease.
Similarly, Satoh et al. (32) observed NOS II mRNA in 54% of
dCMP patients, but not in patients with hypertrophic cardio-
myopathy also using RT-PCR. These data indicate that NOS II
is not expressed in all patients with the same etiology and in
addition varies between different types of heart failure. Thus,
the apparent differences between the present findings and
previous findings of others can be explained by the different
methods used. Reverse transcription-polymerase chain reac-
tion is a sensitive method to detect trace amounts of mRNA (1
mole), whereas RNase protection analysis allows the measure-
ment of biologically relevant concentrations of mRNA (in the
range of 0.1 pg). Hence, trace amounts of NOS II mRNA
present in some failing hearts and detected by RT-PCR may
have escaped our RNase protection assays. Furthermore, it is
conceivable that NOS II expression is different in right and left
ventricular tissue. In the present study we used mainly (26 of 30
failing hearts) left ventricular tissue, whereas others (28–32)
investigated NOS II expression in right ventricular tissue.
NOS III expression. We now demonstrate NOS III mRNA
and protein both in failing and NF myocardium. We found
NOS III mRNA levels increased in failing hearts: dCMP
;180%, iCMP ;200% and mCMP ;210%, compared with
NF hearts (100%). Accordingly, on Western blots increased
expression of NOS III protein was detected in failing hearts as
compared to NF hearts. One may hypothesize that such an
increase results from an enhanced expression in endothelial
cells. However, the immunohistochemical results argue against
this interpretation. We found similar NOS III staining inten-
sities in the endothelium of blood vessels from failing and NF
hearts. In contrast, NOS III immunoreactivity in normal
myocardium was clearly intensified in the cardiomyocytes from
failing hearts. Thus, the recently reported elevated plasma
nitrate levels in patients with heart failure (44) may be
explained in part by the increased NOS III expression in
cardiomyocytes. However, the finding of elevated plasma levels
is not undisputed, since others demonstrated decreased NO
production in coronary microvessels from failing human hearts
(45). Furthermore, in studying a dog model for heart failure,
Zaho et al. (46) reported reduced expression of NOS III
mRNA and protein in the aorta of these dogs.
Functional role of NOS III upregulation. Nitric oxide pro-
duction by NOS III within the cardiomyocyte could exert an
effect on myocardial contractility. Recent reports demon-
strated that NO formed by NOS III reduced inotropic respon-
siveness to beta-blockers (8,9,11) and force-frequency relation
(13,14) in the heart, probably by acting via the cGMP signal
cascade to modulate L-type calcium channels (9,47–49). More-
over, it has been shown that the beta-adrenergic hyporespon-
siveness mediated by NO is augmented in an animal model of
heart failure (50). Thus, it is conceivable that an increased
NO-formation due to elevated NOS III expression in the
failing myocardium is involved in the diminished responsive-
ness to beta-blockers and/or the attenuated myocardial force-
frequency relation in human heart failure. However, consider-
able efforts by others failed to support the abovementioned
conclusions (17–21). The present finding of an increased NOS
III expression in cardiomyocytes from failing hearts may be of
pathophysiologic relevance. Recently, it has been demon-
strated that in vivo gene transfection of NOS III into cardio-
myocytes caused apoptosislike cell death and that these mor-
phologic features mimicked acute myocarditis or ischemic
injury (27). Therefore, the increased NOS III expression in
failing hearts may contribute to the morphologic alterations
seen under these conditions.
Conclusion. We conclude that the increased NOS III ex-
pression in ventricular myocardium of failing human hearts
may contribute to the contractile dysfunction observed in heart
failure and/or may play a role in morphologic alterations such
as hypertrophy and apoptosis of cardiomyocytes.
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Peter Kalma´r (Abteilung fu¨r Herz-, Thorax- und Gefa¨ßchirurgie, Universita¨ts-
Krankenhaus Eppendorf, Universita¨t Hamburg, Hamburg, Germany) and Axel
Haverich (Abteilung fu¨r Herz-, Thorax- und Gefa¨ßchirurgie, Universita¨t Kiel,
Kiel, Germany) for cooperation and providing us with ventricular tissue. This
study was supported by the Deutsche Forschungsgemeinschaft.
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